Post-surgical Wounds Clinical Trial
Official title:
Prospective Randomized Controlled Case Series Evaluating the Safety and Efficacy of FBPM10 System When Compared to Standard of Care in the Treatment of Post-surgical Wounds
| Verified date | February 2019 |
| Source | KLOX Technologies Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a prospective randomized controlled case series in patients having a surgery for bilateral breast reduction. Objectives of the case series are to evaluate the safety and efficacy of the FBPM10 System when compared with standard of care (massages with vitamin E cream) in the treatment of post-surgical wounds.
| Status | Completed |
| Enrollment | 5 |
| Est. completion date | June 30, 2018 |
| Est. primary completion date | February 28, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Signed and dated written informed consent form; 2. Female 18 years of age and older; 3. Good general health, stable weight, free of systemic diseases such as diabetes, arthritis, HIV infection or genetic disorder that could influence the outcome of the treatment; 4. Fitzpatrick skin type I to III; 5. Patients with bilateral breast reduction, expected to have newly formed post-surgery breast incisions of comparable length and of comparable appearance, located on comparable skin area; 6. Patients able to understand, willing and able to comply with all study requirements and post-operative instructions. Exclusion Criteria: 1. Inability to understand the Study and its requirements or to give informed consent; 2. Systemic antibiotic therapy or anti-inflammatory drugs or any other medication(s) that might interfere with healing within the last three months prior to Treatment initiation; 3. Current use of anticoagulants such as (but not limited to) warfarin, clopidogrel, enoxaparin or high doses of aspirin (> 162 mg daily); 4. Female pregnant patient (by medical history or as ascertained by a pregnancy test); 5. Patient with current alcohol use or actively consuming drugs (addiction) as it may interfere with patient's ability to comply with Study procedures; 6. Patient with known photosensitivity, taking drug(s) to treat photosensitivity, with concurrent disease (such as porphyria) or drug(s) (such as methotrexate or chloroquine) known to induce severe photosensitivity of the skin; 7. Patients who are immunocompromised or taking immunosuppressive therapy; 8. Any concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the Study investigational device; 9. Patient has ongoing malignant disease of any type, active systemic, local skin infection or disease, autoimmune disease or any significant chronic disease which, in the opinion of the investigator, might interfere with the evaluation of the Study objectives or would result in non-compliance with the Study protocol; 10. Patients having had surgery in the area to be incised within one year of Study Screening; 11. Patients with tattoos in the areas of incisions; 12. Patients with history or familial history of keloids or hypertrophic scars; 13. Patients with incisions that are actively bleeding; 14. Patients with known skin hypersensitivity; 15. Patients with known allergic reactions to silicone. 16. Patients that cannot start the treatment within 14 days of the surgery. |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Victoria Park Medispa | Montreal | Quebec |
| Lead Sponsor | Collaborator |
|---|---|
| KLOX Technologies Inc. |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | External echography | Assessment of the aspect and depth of the dermal and epidermal superficial subcutaneous tissues in the two treatment groups | Up to 24 weeks | |
| Primary | Adverse events, Serious adverse events, device incidents and compliance | Number of adverse events, serious adverse events, device incidents and missed treatment visits | Up to 24 weeks | |
| Secondary | Patient and Observer Scar Assessment Scale (POSAS) | Assessment of the efficacy of FBPM10 and standard of care by the patient and by the investigator via the POSAS | Up to 24 weeks | |
| Secondary | Vancouver Scar Scale (VSS) | Assessment of the efficacy of FBPM10 and standard of care by the investigator via the VSS | Up to 24 weeks | |
| Secondary | Ease of wound management | Patient's self-assessment of ease of wound management by a specific questionnaire | Up to 24 weeks |